Search fresh public links, source activity, and ready-to-use post angles for Glp-1 Ras (Drug).
Fresh curated links around GLP-1 RAs (Drug) are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The widespread use of drugs like Ozempic is giving scientists a clearer picture than ever of their effects.
A new oral GLP-1 medication helped people with type 2 diabetes dramatically improve blood sugar control and lose weight in a major clinical trial. The results suggest that highly e...
Use of GLP-1s was associated with significantly reduced risk for hepatic complications among patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabe...
The study compared three types of the medication: tirzepatide (better known under the brand names Zepbound and Mounjaro), semaglutide (sold as Wegovy and Ozempic), and liraglutide...
WEDNESDAY, May 27, 2026 — A new study suggests GLP-1 medications may slow the spread of certain obesity-related cancers. "GLP-1 receptor agonists have never been just glucose-lower...
A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. Resea...
NEW ORLEANS — Individuals with obesity and autoimmune diseases who use a GLP-1 receptor agonist may have lower risk for mortality, fewer cardiovascular and thrombotic events and lo...
The study compared three types of the medication: tirzepatide (better known under the brand names Zepbound and Mounjaro), semaglutide (sold as Wegovy and Ozempic), and liraglutide...
GLP-1 medications have exploded in popularity over the past few years, and it’s easy to see why. They work. People lose significant weight, blood sugar improves, and for the first...
WEDNESDAY, June 10, 2026 — Another GLP-1 pill could be headed for the market soon, according to early clinical trial results. The once-daily experimental pill elecoglipron helped p...
GLP-1 receptor agonists, particularly new generation agents such as semaglutide and tirzepatide, may significantly reduce the risk for arthroplasty in patients with knee osteoarthr...
What started as a diabetes medication has rapidly become one of the most talked-about drug categories in modern medicine. GLP-1 medications such as Ozempic, Wegovy,...
Interesting GLP-1 study in a large, matched Type 2 diabetes patient cohort.
New research links GLP-1 drugs to reduced cancer risk across several types, though experts say more studies are needed.
GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, researchers report.
WEDNESDAY, June 3, 2026 — Taking Ozempic or Zepbound might lower a woman’s risk of breast cancer, a new study says.Women with excess weight taking GLP-1 drugs were about 30% less...
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordis...
GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual me...
Not long ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were primarily the domain of endocrinologists.
While many patients are seeing life-changing results with GLP-1 medications, doctors say the medications can also come with risks if they are not dosed properly.
Experts are intrigued by the theory. Here’s what early research suggests.
WEDNESDAY, June 17, 2026 — People with an autoimmune disease and obesity might lower their risk of dangerous blood clots and death by taking Ozempic or Zepbound, a new study says....
Retatrutide is one of those drugs. It helped people lose a massive amount of weight in clinical trials. It also improved sleep apnea and knee pain.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.